On October 18, 2025, Olema Pharmaceuticals announced new data from its Phase 1b/2 trial showing that 72 patients were treated with palazestrant combined with ribociclib for advanced breast cancer, achieving a median progression-free survival of 15.5 months overall, with safety consistent with previous studies.